Cancer Letters,
Год журнала:
2023,
Номер
581, С. 216508 - 216508
Опубликована: Ноя. 28, 2023
Among
patients
with
triple-negative
breast
cancer
(TNBC),
distant
metastasis
is
the
leading
cause
of
death.
Our
previous
studies
have
shown
that
TNBC
progression
greatly
facilitated
by
circKIF4A,
but
uncertainty
remains
regarding
its
role
in
brain
and
molecular
mechanism.
In
this
study,
we
found
notable
upregulation
circKIF4A
cell
lines
metastases.
Inhibition
impaired
ability
to
proliferate,
migrate,
metastasis.
Luciferase
reporter
assays
confirmed
competed
for
binding
miR-637
STAT3
3’
UTR.
Western
blot
analysis
revealed
inhibition
decreased
p62
expression,
while
increased
LC3B-II/LC3B–I
ratio
expression
Beclin,
indicating
downregulation
induced
autophagy
competing
miR-637.
By
employing
a
competitive
endogenous
RNA
(ceRNA)
mechanism,
circKIF4A-miR-637-STAT3
axis
coordinates
TNBC.
can
therefore
be
used
as
prognostic
biomarker
therapeutic
target.
Breast Cancer,
Год журнала:
2024,
Номер
31(4), С. 539 - 551
Опубликована: Апрель 17, 2024
Triple-negative
breast
cancer
(TNBC)
is
a
highly
heterogeneous
tumor
lacking
estrogen
receptor
(ER),
progesterone
(PR),
and
human
epidermal
growth
factor
2
(HER2)
expression.
It
has
higher
aggressiveness
metastasis
than
other
subtypes,
with
limited
effective
therapeutic
strategies,
leading
to
poor
prognosis.
The
phosphoinositide
3-kinase
(PI3K)/protein
kinase
B
(AKT)/mechanistic
target
of
rapamycin
(mTOR)
signaling
pathway
prevalently
over-activated
in
cancers
contributes
(BC)
growth,
survival,
proliferation,
angiogenesis,
which
could
be
an
interesting
target.
This
review
summarizes
the
PI3K/AKT/mTOR
activation
mechanism
TNBC
discusses
relationship
between
its
various
subtypes.
We
also
report
latest
clinical
studies
on
inhibitors
related
this
for
treating
TNBC.
Our
issues
that
need
addressed
application
these
inhibitors.
Theranostics,
Год журнала:
2024,
Номер
15(3), С. 993 - 1016
Опубликована: Дек. 2, 2024
Immunotherapy
has
transformed
current
cancer
management,
and
it
achieved
significant
progress
over
last
decades.
However,
an
immunosuppressive
tumor
microenvironment
(TME)
diminishes
the
effectiveness
of
immunotherapy
by
suppressing
activity
immune
cells
facilitating
immune-evasion.
Adenosine
monophosphate-activated
protein
kinase
(AMPK),
a
key
modulator
cellular
energy
metabolism
homeostasis,
gained
growing
attention
in
anti-tumor
immunity.
Metformin
is
usually
considered
as
cornerstone
diabetes
its
role
activating
AMPK
pathway
also
been
extensively
explored
therapy
although
findings
on
remain
inconsistent.
nanomedicine
formulation
found
to
hold
potential
reprogramming
TME
through
immunometabolic
modulation
both
cells.
This
review
elaborates
foundation
via
metformin-based
nanomedicines,
offering
valuable
insights
for
next
generation
therapy.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(10), С. 5489 - 5489
Опубликована: Май 17, 2024
Over
120
small-molecule
kinase
inhibitors
(SMKIs)
have
been
approved
worldwide
for
treating
various
diseases,
with
nearly
70
FDA
approvals
specifically
cancer
treatment,
focusing
on
targets
like
the
epidermal
growth
factor
receptor
(EGFR)
family.
Kinase-targeted
strategies
encompass
monoclonal
antibodies
and
their
derivatives,
such
as
nanobodies
peptides,
along
innovative
approaches
use
of
degraders
protein
interaction
inhibitors,
which
recently
demonstrated
clinical
progress
potential
in
overcoming
resistance.
Nevertheless,
kinase-targeted
encounter
significant
hurdles,
including
drug
resistance,
greatly
impacts
benefits
patients,
well
concerning
toxicity
when
combined
immunotherapy,
restricts
full
utilization
current
treatment
modalities.
Despite
these
challenges,
development
remains
highly
promising.
The
extensively
studied
tyrosine
family
has
70%
its
stages
development,
while
30%
inadequately
explored.
Computational
technologies
play
a
vital
role
accelerating
novel
repurposing
existing
drugs.
Recent
FDA-approved
SMKIs
underscore
importance
blood-brain
barrier
permeability
long-term
patient
benefits.
This
review
provides
comprehensive
summary
recent
based
mechanisms
action
targets.
We
summarize
latest
developments
new
explore
emerging
inhibition
from
perspective.
Lastly,
we
outline
obstacles
future
prospects
inhibition.
Cell Death Discovery,
Год журнала:
2024,
Номер
10(1)
Опубликована: Янв. 5, 2024
Abstract
Breast
cancer
is
the
second
leading
cause
of
death
in
women
worldwide,
with
triple-negative
breast
(TNBC)
having
worst
prognosis.
Although
there
are
numerous
studies
on
TNBC,
no
effective
treatment
for
it,
and
it
still
a
major
problem
today.
Studies
PIWI-interacting
RNAs
(piRNAs)
increasing
investigating
mechanism
piRNAs
proliferation
metastasis
TNBC
may
lead
to
new
potential
targets.
Here,
we
identified
novel
piRNA,
piR-YBX1,
which
was
downregulated
compared
matched
normal
tissue.
Overexpression
piR-YBX1
significantly
inhibited
proliferation,
migration,
invasion
ability
cells
both
vivo
vitro.
Mechanistically,
could
bind
directly
mRNA
Y-box
binding
protein
1
(
YBX1
)
overexpression
levels,
while
function
be
partly
rescued
by
YBX1.
In
addition,
RAF1
key
molecule
MAPK
signaling
pathway,
p-MEK
p-ERK1/2,
can
reverted
conclusion,
our
findings
discovered
that
piR-YBX1/YBX1/MAPK
axis
suppresses
therefore
has
an
therapeutic
agent
cancer.
Abstract
Breast
cancer
is
a
complex
and
heterogeneous
disease,
encompassing
various
subtypes
characterized
by
distinct
molecular
features,
clinical
behaviors,
treatment
responses.
Categorization
of
based
on
the
presence
or
absence
estrogen
receptor
(ER),
progesterone
(PR),
human
epidermal
growth
factor
2
(HER2),
leading
to
such
as
luminal
A,
B,
HER2-positive,
triple-negative
breast
(TNBC).
TNBC,
comprising
around
20%
all
cancers,
lacks
expression
ER,
PR,
HER2
receptors,
rendering
it
unresponsive
targeted
therapies
presenting
significant
challenges
in
treatment.
TNBC
associated
with
aggressive
behavior,
high
rates
recurrence,
resistance
chemotherapy.
Tumor
initiation,
progression,
are
attributed
stem
cells
(BCSCs),
which
possess
self-renewal,
differentiation,
tumorigenic
potential.
Surface
markers,
self-renewal
pathways
(Notch,
Wnt,
Hedgehog
signaling),
apoptotic
protein
(Bcl-2),
angiogenesis
inhibition
(VEGF
inhibitors),
immune
modulation
(cytokines,
checkpoint
inhibitors)
among
key
targets
discussed
this
review.
However,
targeting
BCSC
subpopulation
presents
challenges,
including
off-target
effects,
low
solubility,
bioavailability
anti-BCSC
agents.
Nanoparticle-based
offer
promising
approach
target
cellular
processes
implicated
survival
BSCS
TNBC.
In
review,
we
explore
nanocarrier-based
approaches
for
BCSCs
aiming
overcome
these
improve
outcomes
patients.
These
nanoparticle-based
therapeutic
strategies
hold
promise
addressing
gap
delivering
while
minimizing
systemic
toxicity
enhancing
efficacy.
Graphical
abstract
Human Vaccines & Immunotherapeutics,
Год журнала:
2024,
Номер
20(1)
Опубликована: Апрель 2, 2024
Breast
cancer
is
the
leading
cause
of
cancer-related
death
among
women
globally.
Immunotherapy
has
emerged
as
a
major
milestone
in
contemporary
oncology.
This
study
aims
to
conduct
bibliometric
analysis
field
immunotherapy
for
breast
cancer,
providing
comprehensive
overview
current
research
status,
identifying
trends
and
hotspots
topics.
We
searched
retrieved
data
from
Web
Science
Core
Collection,
performed
publications
on
2013
2022.
Current
status
were
evaluated
by
co-occurrence
using
VOSviewer.
Evolution
bursts
knowledge
base
assessed
co-citation
CiteSpace.
Thematic
evolution
bibliometrix
package
was
used
discover
keywords
trends.
The
attribution
collaboration
countries/regions,
institutions
authors
also
explored.
A
total
7,975
included.
In
keywords,
6
clusters
revealed:
tumor
microenvironment,
prognosis
biomarker,
immune
checkpoints,
novel
drug
delivery
methods,
cells
therapeutic
approaches.
top
three
most
frequently
mentioned
triple-negative
programmed
cell
ligand
1.
productive
country,
institution
author
USA
(2926
publications),
University
Texas
MD
Anderson
Cancer
Center
(219
Sherene
Loi
(28
respectively.
There
been
rapid
growth
studies
worldwide.
area
gained
increasing
attention
different
countries
institutions.
With
rising
incidence
represents
significant
clinical
value
potential.
